{"success":true,"data":{"pressRelease":{"id":"74885","rtpr_id":"nGNE3H3Jm","ticker":"ZLNA","exchange":"Oslo Børs","all_tickers":["ZLNA"],"title":"REG-Zelluna ASA: New share capital registered","author":"Globe Newswire","published_at":"2026-06-29T07:59:05.065Z","article_body":"Oslo, Norway, 29 June 2026: Reference is made to the stock exchange\nannouncement published by Zelluna ASA (the “Company”) on 18 June 2026\nregarding a successfully placed private placement (the “Private\nPlacement”) and a retail offering (the “Retail Offering”) as described\ntherein. Reference is also made to the resolution of the Board of Directors of\nthe Company to issue 2,972,973 new shares in the Company in the Private\nPlacement and 170,985 new shares in the Company in the Retail Offering at a\nsubscription price of NOK 18.50 per share, raising gross proceeds of\napproximately NOK 58.2 million, pursuant to an authorisation granted by the\nCompany’s general meeting on 23 April 2026.\n\nThe share capital increases pertaining to the Private Placement and the Retail\nOffering have today been registered with the Norwegian Register of Business\nEnterprises (Nw. Foretaksregisteret). Following the registration, the\nCompany's new share capital is NOK 29,413,759, divided into 29,413,759\nordinary shares, each with a nominal value of NOK 1.00.\n\nFor further information, please visit www.zelluna.com or contact:\n\nNamir Hassan, CEO\nEmail: namir.hassan@zelluna.com\nPhone: +44 7720 687608\n\nGeir Christian Melen, CFO\nEmail: geir.christian.melen@zelluna.com\nPhone: +47 913 02 965\n\n***\n\nThis information is subject to the disclosure requirements pursuant to section\n5-12 of the Norwegian Securities Trading Act.\n\nAbout Zelluna ASA\nZelluna ASA (OSE: ZLNA) is a company pioneering allogeneic 'off-the-shelf' T\nCell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment\nof solid cancers. The company's platform combines the innate killing power of\nNK cells with precise solid tumour targeting of TCRs, designed to address the\nlimitations of current cell therapies in solid tumours. The company's lead\ncandidate, ZI-MA4-1, is the world's first MAGE-A4 targeting TCR-NK therapy\nexpected to enter clinical development trials in 2026. Zelluna is\nheadquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway and\nis listed on the Oslo Stock Exchange under the ticker ZLNA.","article_body_html":"","raw_payload":{"data":{"id":"nGNE3H3Jm","title":"REG-Zelluna ASA: New share capital registered","author":"Globe Newswire","ticker":"ZLNA","created":"2026-06-29T07:59:05.065Z","tickers":["ZLNA"],"exchange":"Oslo Børs","article_body":"Oslo, Norway, 29 June 2026: Reference is made to the stock exchange\nannouncement published by Zelluna ASA (the “Company”) on 18 June 2026\nregarding a successfully placed private placement (the “Private\nPlacement”) and a retail offering (the “Retail Offering”) as described\ntherein. Reference is also made to the resolution of the Board of Directors of\nthe Company to issue 2,972,973 new shares in the Company in the Private\nPlacement and 170,985 new shares in the Company in the Retail Offering at a\nsubscription price of NOK 18.50 per share, raising gross proceeds of\napproximately NOK 58.2 million, pursuant to an authorisation granted by the\nCompany’s general meeting on 23 April 2026.\n\nThe share capital increases pertaining to the Private Placement and the Retail\nOffering have today been registered with the Norwegian Register of Business\nEnterprises (Nw. Foretaksregisteret). Following the registration, the\nCompany's new share capital is NOK 29,413,759, divided into 29,413,759\nordinary shares, each with a nominal value of NOK 1.00.\n\nFor further information, please visit www.zelluna.com or contact:\n\nNamir Hassan, CEO\nEmail: namir.hassan@zelluna.com\nPhone: +44 7720 687608\n\nGeir Christian Melen, CFO\nEmail: geir.christian.melen@zelluna.com\nPhone: +47 913 02 965\n\n***\n\nThis information is subject to the disclosure requirements pursuant to section\n5-12 of the Norwegian Securities Trading Act.\n\nAbout Zelluna ASA\nZelluna ASA (OSE: ZLNA) is a company pioneering allogeneic 'off-the-shelf' T\nCell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment\nof solid cancers. The company's platform combines the innate killing power of\nNK cells with precise solid tumour targeting of TCRs, designed to address the\nlimitations of current cell therapies in solid tumours. The company's lead\ncandidate, ZI-MA4-1, is the world's first MAGE-A4 targeting TCR-NK therapy\nexpected to enter clinical development trials in 2026. Zelluna is\nheadquartered at the Oslo Cancer Cluster Innovation Park in Oslo, Norway and\nis listed on the Oslo Stock Exchange under the ticker ZLNA."},"type":"article","timestamp":"2026-06-29T07:59:05.147116054Z","server_sent_at_ms":1782719945147},"received_at":"2026-06-29T07:59:05.213Z","source_url":null},"analysis":{"id":"64243","press_release_id":"74885","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"offering","narrative":"Zelluna ASA confirmed the registration of its new share capital following the completion of a private placement and retail offering announced on June 18.\n\nThe company issued a total of 3,143,958 new shares (2,972,973 in the private placement and 170,985 in the retail offering) at NOK 18.50 per share.\n\nGross proceeds from the combined offerings were approximately NOK 58.2 million, bringing the total share capital to NOK 29,413,759 divided into 29,413,759 ordinary shares.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine post-offering registration for ZLNA; no new material news."},"keyFigures":{"offeringPrice":"NOK 18.50","customDimensions":{"nominal_value_nok":1,"gross_proceeds_nok":58200000,"new_share_capital_nok":29413759,"total_shares_outstanding":29413759}},"quotedText":"The share capital increases pertaining to the Private Placement and the Retail Offering have today been registered with the Norwegian Register of Business Enterprises","namedEntities":{"people":[{"name":"Namir Hassan","role":"CEO"},{"name":"Geir Christian Melen","role":"CFO"}],"products":["ZI-MA4-1"],"companies":[{"name":"Zelluna ASA","ticker":"ZLNA","relationship":"filer"},{"name":"Norwegian Register of Business Enterprises","relationship":"regulator"}],"dollarAmounts":[{"amount":"NOK 58.2 million","context":"gross proceeds from private placement and retail offering"},{"amount":"NOK 18.50","context":"subscription price per share"},{"amount":"NOK 29,413,759","context":"new total share capital"},{"amount":"NOK 1.00","context":"nominal value per share"}]},"materialImpact":{"score":2,"reasoning":"This is a routine administrative confirmation that a previously announced private placement and retail offering have been registered. The capital raise (~NOK 58.2M) was disclosed on June 18; this release adds no new material information, only the final share count and capital registration."},"tickerRelevance":{"others":[],"primary":"ZLNA"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"administrative_registration","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"offering","event_type_secondary":null,"sentiment":"neutral","material_impact_score":2,"narrative":"Zelluna ASA confirmed the registration of its new share capital following the completion of a private placement and retail offering announced on June 18.\n\nThe company issued a total of 3,143,958 new shares (2,972,973 in the private placement and 170,985 in the retail offering) at NOK 18.50 per share.\n\nGross proceeds from the combined offerings were approximately NOK 58.2 million, bringing the total share capital to NOK 29,413,759 divided into 29,413,759 ordinary shares.","key_figures":{"offeringPrice":"NOK 18.50","customDimensions":{"nominal_value_nok":1,"gross_proceeds_nok":58200000,"new_share_capital_nok":29413759,"total_shares_outstanding":29413759}},"named_entities":{"people":[{"name":"Namir Hassan","role":"CEO"},{"name":"Geir Christian Melen","role":"CFO"}],"products":["ZI-MA4-1"],"companies":[{"name":"Zelluna ASA","ticker":"ZLNA","relationship":"filer"},{"name":"Norwegian Register of Business Enterprises","relationship":"regulator"}],"dollarAmounts":[{"amount":"NOK 58.2 million","context":"gross proceeds from private placement and retail offering"},{"amount":"NOK 18.50","context":"subscription price per share"},{"amount":"NOK 29,413,759","context":"new total share capital"},{"amount":"NOK 1.00","context":"nominal value per share"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-29T07:59:15.952Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"administrative_registration","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":10731,"modelName":"george-droid-qwen-72b"}}